Drug intelligence / Profile preview

OHB-401

Development stage: Unknown
Lead developer: Oak Hill Bio
Modality: Small Molecules
Administration: Oral

Overview

OHB-401 is an oral small molecule plasma kallikrein (KLKB1) inhibitor under development by Oak Hill Bio. Its primary mechanism of action is the inhibition of plasma kallikrein, a serine protease involved in the generation of bradykinin and regulation of vascular permeability and inflammation. By inhibiting KLKB1, OHB-401 aims to reduce inflammation and edema associated with diabetic macular edema (DME), a leading cause of vision loss in diabetic patients. The drug leverages years of research into pKAL inhibition and is positioned as a potential best-in-class therapy for DME[1][2][4].

Targets

KLKB1 (Plasma kallikrein)

Beyond the preview

Go deeper on OHB-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OHB-401.

Explore the full profile